[ad_1]
San Diego, December 10, 2021 (Global News Agency)- Robbins Geller Rudman & Dowd LLP Announcing the purchaser or acquirer: (1) Silverback Therapeutics Inc. (NASDAQ:SBTX) Ordinary shares, based on and/or traceable to issuance documents related to the initial public offering (“IPO”) of Silverback Therapeutics on or about December 3, 2020; and/or (2) Silverback Therapeutics securities in 2020 From December 3 to September 10, 2021 (both dates inclusive) (the “class action period”), the appointment as lead plaintiff must be sought before January 4, 2022 Dresner v. Silverback Therapeutics, Inc., No. 21-cv-01499 (WD Wash.). From November 5, 2021, Silver back therapy The class action alleges that Silverback Therapeutics and certain executives and directors violated the Securities Act of 1933 and/or the Securities Exchange Act of 1934.
If you want to be the lead plaintiff Silver back therapy Class action, please Click here to provide your information. You can also contact a lawyer JC Sanchez Robbins Geller call 800/449-4900 or send an email to jsanchez@rgrdlaw.com. Lead the plaintiff’s motion Silver back therapy The class action must be filed in court before January 4, 2022.
Case allegations: The main product candidate of Silverback Therapeutics is SBT6050, which is in phase 1/1b clinical trials. This is a TLR8 agonist linker payload that binds to HER2-directed monoclonal antibodies to target tumors such as breast cancer, gastric cancer and Non-small cell lung cancer. On November 10, 2020, Silverback Therapeutics submitted a registration statement regarding…
The full story can be found on Benzinga.com
[ad_2]
Source link
